Wall Street Zen Downgrades Arcus Biosciences (NYSE:RCUS) to Sell

Arcus Biosciences (NYSE:RCUS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

RCUS has been the topic of several other research reports. Wells Fargo & Company raised their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Truist Financial set a $30.00 target price on shares of Arcus Biosciences in a research note on Friday, December 12th. HC Wainwright boosted their price target on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Finally, Citigroup reaffirmed a “buy” rating on shares of Arcus Biosciences in a report on Friday, December 12th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $28.67.

Arcus Biosciences Stock Down 1.6%

Shares of NYSE:RCUS opened at $21.02 on Friday. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.27 billion, a P/E ratio of -6.11 and a beta of 0.77. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $26.40. The company’s 50-day moving average price is $22.60 and its two-hundred day moving average price is $15.54.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. Arcus Biosciences’s quarterly revenue was down 45.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.00) earnings per share. As a group, research analysts forecast that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

Insider Transactions at Arcus Biosciences

In related news, CEO Terry J. Rosen sold 28,947 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total transaction of $633,360.36. Following the completion of the transaction, the chief executive officer directly owned 2,220,553 shares in the company, valued at approximately $48,585,699.64. This trade represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jennifer Jarrett sold 11,225 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $245,603.00. Following the completion of the sale, the chief operating officer owned 203,007 shares in the company, valued at $4,441,793.16. The trade was a 5.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 422,060 shares of company stock valued at $9,286,202 over the last three months. Company insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RCUS. GAMMA Investing LLC grew its position in Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after acquiring an additional 2,845 shares in the last quarter. CWM LLC grew its holdings in shares of Arcus Biosciences by 233.6% in the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after acquiring an additional 3,810 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after acquiring an additional 1,796 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Arcus Biosciences by 440.3% during the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after acquiring an additional 6,191 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.